MetriDx
Diagnostic TestBiopsied tissue will be analyze by proprietary LDT, MetriDx, and compared to laparoscopy diagnostic report on record
NCT Number: NCT05698212
This study is testing a way to diagnose endometriosis using a uterine tissue biopsy (similar to a pap smear) as opposed to undergoing laparoscopy surgery. The tissue is sent to lab for cellular analysis with a proprietary AI (artificial intelligence) technology.
Interested in participating?
Request Info18 year–50 year
Female
Interventional
Phase 2
Valley OB-GYN Clinic, PC, Saginaw, Michigan, United States
This study involves 2 visits to the site and possibly as outpatient surgical center, and the participant will be involved in the for as little as 1 day to as much as 60 days, mainly depending on scheduling of laparoscopy. Eligible participants in the active group will have history of endometriosis and will be having a laparoscopy for diagnosis within the next few weeks. Eligible participants in the control group will have no history of endometriosis but will need or have recently had a laparoscopy surgical procedure for a reasons such as tubal ligation.
The participant will have an uterine biopsy (similar to a pap smear) in the physician's office before the laparoscopy. The biopsied tissue will be sent to a special lab for analysis and diagnosis of endometriosis by an innovative proprietary procedure that analyses the cells of the tissue collected in the biopsy.
The results of the biopsy will be compared to the laparoscopy for accuracy.
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Biopsied tissue will be analyze by proprietary LDT, MetriDx, and compared to laparoscopy diagnostic report on record
Time frame: 1 week after laparoscopy
Endometriosis diagnosis
Time frame: 1 week after laparoscopy
Accurate staging of endometriosis
Time frame: 1 week after providing menstrual effluent sample
observe and explore any relationship between subject's estrogen and progesterone levels and MetriDx results.
Contact information is provided by the study sponsor or research team.
Hera Biotech, Inc.
Industry
Proof-of-Concept, Obs Study to Evaluate Accuracy of MetriDx Lab Developed Test (LDT) to Accurately Identify Endometriosis-specific Biological Markers Using Micro-fluidic Analysis of Cells Enabling Clinicians to Diagnose Endometriosis
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT05779462
Comparative Study, Diagnosis
Lille, France
View Trial DetailsNCT06245512
Disease, Endometriosis
Paris, France
View Trial DetailsNCT05523284
Disease, Endometriosis
Hamilton, Ontario, Canada
View Trial DetailsNCT05601596
Disease, Endometriosis
Manhasset, New York, United States
View Trial Details